Kinnate Biopharma Inc. KNTE
Set alert
2.65 0.00 0.00%
At close · Apr 2
2.64 Day range 2.68
52-week range unavailable
- Open
- 2.65
- Prev close
- 2.65
- Mkt cap
- 124.99M
- Vol
- 2.12M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.64
- High
- 2.68
- Forward P/E
- -2.55
- Beta
- 1.34
- Short ratio
- 0.96
- Inst. own
- 82.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 9, 2024
- 50-d avg
- 2.49
- 200-d avg
- 2.24
- 1y target
- 2.36
Analyst view
Consensus: buy
Buy
Price target (mean) 2.36 -10.9% downside
Now 2.65
- Target (low)
- 2.00
- Target (mean)
- 2.36
- Target (high)
- 2.59
Recommendation trend
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.34 | -0.38 – -0.29 | -0.73 | +53.4% | 0 | 0.0% | 3 |
| Next quarter | -0.34 | -0.38 – -0.29 | -0.68 | +50.0% | 0 | 0.0% | 3 |
| Current year | -1.31 | -1.48 – -1.04 | -2.42 | +45.9% | 0 | 0.0% | 3 |
| Next year | -1.04 | -1.55 – -0.71 | -1.31 | +20.6% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2023 | Jefferies | Maintained | Buy | Buy |
| Sep 18, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Sep 18, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Sep 18, 2023 | Piper Sandler | Downgrade | Overweight | Neutral |
| Aug 14, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 11, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| May 11, 2023 | Stifel | Maintained | Hold | Hold |
| Apr 19, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 18, 2023 | Goldman Sachs | Maintained | — | Buy |
| Apr 17, 2023 | Goldman Sachs | Maintained | — | Buy |
| Mar 19, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 15, 2023 | Stifel | Maintained | — | Hold |
| Mar 15, 2023 | Wedbush | Maintained | — | Outperform |
| Nov 16, 2022 | Stifel | Downgrade | Buy | Hold |
| Jul 27, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| May 23, 2022 | Goldman Sachs | Maintained | — | Buy |
| May 18, 2022 | Piper Sandler | Maintained | — | Overweight |
| Sep 26, 2021 | Jefferies | Initiated | — | Buy |
| Sep 22, 2021 | Stifel | Initiated | — | Buy |
| Jul 12, 2021 | William Blair | Initiated | — | Outperform |
| Dec 27, 2020 | Piper Sandler | Initiated | — | Overweight |
| Dec 27, 2020 | SVB Leerink | Initiated | — | Outperform |